News

HDA UK Media And Political Bulletin – 21 November 2017

Media and Political Bulletin

21 November 2017

The HDA would like to thank all those that attended the Business Day on Thursday 16th November in York. The presentations from all the speakers are now available to view on the website. If you would like to view these presentations, please click here.

Media Summary

Amsterdam wins fight for EU medical agency

Financial Times, Mehreen Khan, Jim Brunsden, Sarah Neville, 20 November 2017

 

The Financial Times reports that Amsterdam has won the contest to become the new home of the European Medicines Agency, after its relocation from London post-Brexit. The publication highlights that Amsterdam beat Milan in a head-to-head competition after both cities were tied in a final round vote. The winner was decided with the name being picked out of a hat. Copenhagen came in third place with Bratislava in fourth.

The EMA’s executive director, Guido Rasi, said Amsterdam “ticks many of our boxes”, offering “excellent connectivity and a building that can be shaped according to our needs”. However, he warned that, even though internal surveys had shown “a large majority of EMA staff” would be willing to move with the agency to Amsterdam, “even in this case, our activities will be impacted and we need to plan for this now to avoid the creation of gaps in knowledge and expertise”.

The decision on the relocation of the EMA was also reported in The TimesThe Pharmaceutical JournalPharmaphorumEuropean Pharmaceutical Review and the BBC.

 

 

Response to European Medicines Agency location decision

ABPI, 20 November 2017

 

Following the European Union’s General Affairs Council decision to select Amsterdam, as the new location for the European Medicines Agency, the Association of the British Pharmaceutical Industry issued the following statement.

​Commenting on the decision, Mike Thompson, ABPI Chief Executive said:

“Congratulations to Amsterdam, The Netherlands on their successful bid. Hosting the EMA is a singular honour for any city and we will do all we can to support the agency’s smooth transition to its new home.

“Up to now the focus has inevitably been on the future location of the EMA. But today’s decision marks the moment when attention should switch to how patient safety and effective public health can be maintained during this complex transition and into the future.

“We now urge both the UK and the EU to put patients first and acknowledge that securing a comprehensive agreement to cooperate on medicines safety, regulation and supply is an urgent negotiating priority.”

 

 

Parliamentary Coverage

 

There has been a strong reaction to the EMA relocation from both the political parties and individual MPs, particularly from Shadow Health Secretary Jonathan Ashworth and Liberal Democrat leader Sir Vince Cable.

 

Full Coverage

Amsterdam wins fight for EU medical agency

Financial Times, Mehreen Khan, Jim Brunsden, Sarah Neville, 20 November 2017

 

And the winner is… Amsterdam.

The Dutch city has won a dramatic contest to become the new home of the European Medicines Agency, which is relocating from London after Brexit.

Amsterdam beat Milan in a head-to-head fight after the two cities were tied in a final round vote. The winner was decided with the name being picked out of a hat. The EMA is considered one of jewels in the EU’s network of agencies and will bring with it 900 jobs.

Copenhagen came in third place with Bratislava in fourth. Slovakia abstained in the final vote which was slip 16-16 between Italy and the Netherlands.

EU27 foreign ministers will now begin voting on the new home for the European Banking Authority. Frankfurt, Paris and Dublin will be contesting the second round vote.

The Association of the British Pharmaceutical Industry (ABPI) – the trade group for the pharmaceutical industry in the UK – welcomed the decision to select Amsterdam and said it would do all it could “to support the agency’s smooth transition to its new home”.

Mike Thompson, chief executive, said attention should now switch “to how patient safety and effective public health can be maintained during this complex transition and into the future”.

Both the UK and the EU should make “securing a comprehensive agreement to cooperate on medicines safety, regulation and supply an urgent negotiating priority,” he added.

Amsterdam has proven to be one of the early winners from relocations after Brexit. A number of banks and trading houses have already announced their moves to the Dutch city.

The EMA’s executive director, Guido Rasi, said Amsterdam “ticks many of our boxes”, offering “excellent connectivity and a building that can be shaped according to our needs”.

However, he warned that, even though internal surveys had shown “a large majority of EMA staff” would be willing to move with the agency to Amsterdam, “even in this case, our activities will be impacted and we need to plan for this now to avoid the creation of gaps in knowledge and expertise”.

Monday’s decision “marks the official start of a challenging joint relocation project that will have to be delivered within extremely tight timelines”, the agency said, with the relocation to be completed by March 30, 2019.

Effective collaboration between the EMA and the Netherlands “on the basis of the commitments made in its offer to host EMA is essential to ensure a successful move and the continuation of EMA’s operations with minimal disruption”, it said.

 

Response to European Medicines Agency location decision

ABPI, 20 November 2017

 

Following the European Union’s (EU) General Affairs Council decision to select Amsterdam, The Netherlands as the new location for the European Medicines Agency (EMA), the Association of the British Pharmaceutical Industry (ABPI) – the trade group for the pharmaceutical industry in the UK – have issued the following statement.

​Commenting on the decision, Mike Thompson, ABPI Chief Executive said:

“Congratulations to Amsterdam, The Netherlands on their successful bid. Hosting the EMA is a singular honour for any city and we will do all we can to support the agency’s smooth transition to its new home.

“Up to now the focus has inevitably been on the future location of the EMA. But today’s decision marks the moment when attention should switch to how patient safety and effective public health can be maintained during this complex transition and into the future.

“We now urge both the UK and the EU to put patients first and acknowledge that securing a comprehensive agreement to cooperate on medicines safety, regulation and supply is an urgent negotiating priority.”

HDA UK Media And Political Bulletin – 21 November 2017

From Factory to Pharmacy

As part of our mission to build awareness, understanding and appreciation of the vital importance of the healthcare distribution sector, we developed an infographic explaining the availability of medicines. It identifies the factors that can impact drug supply, as well as the measures that HDA members undertake day in, day out to help mitigate the risks of patients not receiving their medicines.

See the Infographic

Apply to become a Member

Membership of the HDA guarantees your organisation:

  • Access to leading policy and industry forums of debate and discussion
  • Invitations to a range of networking industry events organised through the year, including an Annual Conference and a Business Day
  • Representation on HDA working parties, including the Members’ Liaison Group
  • A daily Political and Media Bulletin and HDA Newsletters
  • Access to HDA policy documents and all sections of the HDA website
  • Branding and marketing opportunities
Apply Now

Already a Member?